The estimated Net Worth of Carolyn C. Tang is at least $739 Thousand dollars as of 16 December 2022. Ms Tang owns over 2,523 units of Arcus Biosciences Inc stock worth over $485,070 and over the last 4 years she sold RCUS stock worth over $254,392.
Ms has made over 4 trades of the Arcus Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 2,523 units of RCUS stock worth $77,582 on 16 December 2022.
The largest trade she's ever made was selling 2,922 units of Arcus Biosciences Inc stock on 16 June 2022 worth over $62,677. On average, Ms trades about 861 units every 50 days since 2021. As of 16 December 2022 she still owns at least 28,584 units of Arcus Biosciences Inc stock.
You can see the complete history of Ms Tang stock trades at the bottom of the page.
Carolyn C. Tang J.D. is the Gen. Counsel & Corp. Sec. at Arcus Biosciences Inc.
Carolyn's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 7 years, insiders at Arcus Biosciences Inc have traded over $12,714,957 worth of Arcus Biosciences Inc stock and bought 22,383,260 units worth $566,530,309 . The most active insiders traders include Patrick Machado, Sciences, Inc. Gilead, and Harbor Master Investors (Ca.... On average, Arcus Biosciences Inc executives and independent directors trade stock every 32 days with the average trade being worth of $5,400,635. The most recent stock trade was executed by Alexander Azoy on 13 August 2024, trading 1,357 units of RCUS stock currently worth $20,314.
arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be
Arcus Biosciences Inc executives and other stock owners filed with the SEC include: